No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
pemetrexed Sensitive: A1 - Approval
|
pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
carboplatin + pemetrexed Sensitive: A2 - Guideline
|
carboplatin + pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
cisplatin + pemetrexed Sensitive: A2 - Guideline
|
cisplatin + pemetrexed Sensitive: A2 - Guideline
|
No biomarker
|
Mesothelioma
|
No biomarker
|
Mesothelioma
|
GC Sensitive: A2 - Guideline
|
GC Sensitive: A2 - Guideline
|
No biomarker
|
Mesothelioma
|
No biomarker
|
Mesothelioma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Mesothelioma
|
No biomarker
|
Mesothelioma
|
cisplatin + raltitrexed Sensitive: A2 - Guideline
|
cisplatin + raltitrexed Sensitive: A2 - Guideline
|
No biomarker
|
Mesothelioma
|
No biomarker
|
Mesothelioma
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
carboplatin + raltitrexed Sensitive: A2 - Guideline
|
carboplatin + raltitrexed Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
GC Sensitive: A2 - Guideline
|
GC Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
ramucirumab Sensitive: A2 - Guideline
|
ramucirumab Sensitive: A2 - Guideline
|
High 4-gene inflammatory score
|
Mesothelioma
|
High 4-gene inflammatory score
|
Mesothelioma
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Malignant Pleural Mesothelioma
|
PD-L1 expression
|
Malignant Pleural Mesothelioma
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Mesothelioma
|
BRCA1 mutation
|
Mesothelioma
|
rucaparib Sensitive: C1 - Off-label
|
rucaparib Sensitive: C1 - Off-label
|
BAP1 mutation
|
Mesothelioma
|
BAP1 mutation
|
Mesothelioma
|
tazemetostat Sensitive: C2 – Inclusion Criteria
|
tazemetostat Sensitive: C2 – Inclusion Criteria
|
MSLN positive
|
Mesothelioma
|
MSLN positive
|
Mesothelioma
|
TC-210 Sensitive: C2 – Inclusion Criteria
|
TC-210 Sensitive: C2 – Inclusion Criteria
|
WT1 expression
|
Malignant Pleural Mesothelioma
|
WT1 expression
|
Malignant Pleural Mesothelioma
|
nivolumab + galinpepimut-S Sensitive: C3 – Early Trials
|
nivolumab + galinpepimut-S Sensitive: C3 – Early Trials
|
TMB-L
|
Malignant Pleural Mesothelioma
|
TMB-L
|
Malignant Pleural Mesothelioma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
TMB-L
|
Malignant Pleural Mesothelioma
|
TMB-L
|
Malignant Pleural Mesothelioma
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 underexpression
|
Malignant Pleural Mesothelioma
|
PD-L1 underexpression
|
Malignant Pleural Mesothelioma
|
PD1 inhibitor Resistant: C3 – Early Trials
|
PD1 inhibitor Resistant: C3 – Early Trials
|
BAP1 negative + BRCA1 mutation
|
Mesothelioma
|
BAP1 negative + BRCA1 mutation
|
Mesothelioma
|
rucaparib Sensitive: C3 – Early Trials
|
rucaparib Sensitive: C3 – Early Trials
|
BAP1 negative
|
Mesothelioma
|
BAP1 negative
|
Mesothelioma
|
rucaparib Sensitive: C3 – Early Trials
|
rucaparib Sensitive: C3 – Early Trials
|
MRE11A mutation
|
Mesothelioma
|
MRE11A mutation
|
Mesothelioma
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
BAP1 mutation
|
Mesothelioma
|
BAP1 mutation
|
Mesothelioma
|
olaparib Resistant: C3 – Early Trials
|
olaparib Resistant: C3 – Early Trials
|
BRCA1 negative
|
Mesothelioma
|
BRCA1 negative
|
Mesothelioma
|
rucaparib Sensitive: C3 – Early Trials
|
rucaparib Sensitive: C3 – Early Trials
|
BAP1 mutation
|
Mesothelioma
|
BAP1 mutation
|
Mesothelioma
|
rucaparib Sensitive: C3 – Early Trials
|
rucaparib Sensitive: C3 – Early Trials
|
ERCC1 expression
|
Malignant Pleural Mesothelioma
|
ERCC1 expression
|
Malignant Pleural Mesothelioma
|
GC Sensitive: C3 – Early Trials
|
GC Sensitive: C3 – Early Trials
|
RRM1 expression
|
Malignant Pleural Mesothelioma
|
RRM1 expression
|
Malignant Pleural Mesothelioma
|
GC Sensitive: C3 – Early Trials
|
GC Sensitive: C3 – Early Trials
|
MSLN overexpression
|
Malignant Pleural Mesothelioma
|
MSLN overexpression
|
Malignant Pleural Mesothelioma
|
TC-210 Sensitive: C3 – Early Trials
|
TC-210 Sensitive: C3 – Early Trials
|
ASS1 mutation
|
Malignant Pleural Mesothelioma
|
ASS1 mutation
|
Malignant Pleural Mesothelioma
|
cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials
|
cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Mesothelioma
|
PD-L1 overexpression
|
Mesothelioma
|
pembrolizumab + nintedanib Sensitive: C3 – Early Trials
|
pembrolizumab + nintedanib Sensitive: C3 – Early Trials
|
CDKN2A negative
|
Mesothelioma
|
CDKN2A negative
|
Mesothelioma
|
abemaciclib Sensitive: C3 – Early Trials
|
abemaciclib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Malignant Pleural Mesothelioma
|
PD-L1 overexpression
|
Malignant Pleural Mesothelioma
|
nivolumab Sensitive: C4 – Case Studies
|
nivolumab Sensitive: C4 – Case Studies
|
EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R
|
Mesothelioma
|
EML4-ALK I1171N + EML4-ALK L1196M + EML4-ALK G1202R
|
Mesothelioma
|
lorlatinib Resistant: C4 – Case Studies
|
lorlatinib Resistant: C4 – Case Studies
|
EML4-ALK I1171N + EML4-ALK L1196M
|
Malignant Pleural Mesothelioma
|
EML4-ALK I1171N + EML4-ALK L1196M
|
Malignant Pleural Mesothelioma
|
alectinib Resistant: C4 – Case Studies
|
alectinib Resistant: C4 – Case Studies
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
STRN exon 2-ALK exon 20 fusion
|
Mesothelioma
|
STRN exon 2-ALK exon 20 fusion
|
Mesothelioma
|
cisplatin + pemetrexed Resistant: C4 – Case Studies
|
cisplatin + pemetrexed Resistant: C4 – Case Studies
|
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)
|
Mesothelioma
|
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)
|
Mesothelioma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)
|
Mesothelioma
|
TMB-L + BAP1 V99M + NF2 R34 + Chr del(14q) + Chr del(19q)
|
Mesothelioma
|
cisplatin + carboplatin + pemetrexed + mitomycin Resistant: C4 – Case Studies
|
cisplatin + carboplatin + pemetrexed + mitomycin Resistant: C4 – Case Studies
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
ABT 263 Sensitive: D – Preclinical
|
ABT 263 Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
cobimetinib Sensitive: D – Preclinical
|
cobimetinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
ceritinib + PF-05212384 Sensitive: D – Preclinical
|
ceritinib + PF-05212384 Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
ensartinib Sensitive: D – Preclinical
|
ensartinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
trametinib Sensitive: D – Preclinical
|
trametinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
cobimetinib + ceritinib Sensitive: D – Preclinical
|
cobimetinib + ceritinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
ceritinib Sensitive: D – Preclinical
|
ceritinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
brigatinib Sensitive: D – Preclinical
|
brigatinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
cisplatin + gemcitabine Resistant: D – Preclinical
|
cisplatin + gemcitabine Resistant: D – Preclinical
|
NF2 mutation
|
Mesothelioma
|
NF2 mutation
|
Mesothelioma
|
CBL0102 Sensitive: D – Preclinical
|
CBL0102 Sensitive: D – Preclinical
|
RB1 deletion
|
Mesothelioma
|
RB1 deletion
|
Mesothelioma
|
BI 6727 Sensitive: D – Preclinical
|
BI 6727 Sensitive: D – Preclinical
|
RB1 deletion
|
Mesothelioma
|
RB1 deletion
|
Mesothelioma
|
MLN8237 Sensitive: D – Preclinical
|
MLN8237 Sensitive: D – Preclinical
|
NF2 mutation
|
Mesothelioma
|
NF2 mutation
|
Mesothelioma
|
verteporfin Sensitive: D – Preclinical
|
verteporfin Sensitive: D – Preclinical
|
LATS1 mutation
|
Mesothelioma
|
LATS1 mutation
|
Mesothelioma
|
verteporfin Sensitive: D – Preclinical
|
verteporfin Sensitive: D – Preclinical
|
LATS2 mutation
|
Mesothelioma
|
LATS2 mutation
|
Mesothelioma
|
verteporfin Sensitive: D – Preclinical
|
verteporfin Sensitive: D – Preclinical
|
RASSF7 amplification
|
Mesothelioma
|
RASSF7 amplification
|
Mesothelioma
|
verteporfin Sensitive: D – Preclinical
|
verteporfin Sensitive: D – Preclinical
|
MSLN overexpression + PD-L1 overexpression
|
Mesothelioma
|
MSLN overexpression + PD-L1 overexpression
|
Mesothelioma
|
ATA3271 Sensitive: D – Preclinical
|
ATA3271 Sensitive: D – Preclinical
|
KRAS mutation
|
Mesothelioma
|
KRAS mutation
|
Mesothelioma
|
IK-930 Sensitive: D – Preclinical
|
IK-930 Sensitive: D – Preclinical
|
EGFR mutation
|
Mesothelioma
|
EGFR mutation
|
Mesothelioma
|
IK-930 Sensitive: D – Preclinical
|
IK-930 Sensitive: D – Preclinical
|